LUMO News and Press, Lumos Pharma Inc. From 04/20/21

AUSTIN, Texas, April 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced several changes to its executive team as the Company celebrates one year since the close of its merger. ...

AUSTIN, Texas, April 14, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that it will host a key opinion leader (KOL) webinar on LUM-201 on Tuesday, April 27, 2021, at 10:30am E...

Up in our gunsights today for analysis is Lumos Pharma, an 'off the radar' small cap concern. This developmental firm out of Austin, Texas, is targeting the rare disease area and is targeting a potential $1B plus indication. A full analysis follows in the paragraphs below. F...

AUSTIN, Texas, March 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the poster 7102 entitled, “ LUM-201 Elicits Greater GH Response than Standard GH Secretagogu...

AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company is participating in the following March 2021 virtual investor conferences: H.C. Wa...

Stifel analyst Derek Archila has upgraded shares of Lumos Pharma (LUMO) from hold to buy and increased his price target from $4 to $24.Based on yesterday's closing price of $13.25, that implies an upside of ~81%.Archila is bullish on shares because LUM-201 for pediatric growth hormone deficie...

Lumos Pharma, Inc. (LUMO) Q4 2020 Earnings Conference Call March 9, 2021 4:30 PM ET Company Participants Lisa Miller – Director-Investor Relations Rick Hawkins – Chief Executive Officer, President and Chairman John McKew – Chief Operating Officer and Chief Scientific Offi...

Lumos Pharma (LUMO): FY GAAP EPS of -$0.93 beats by $0.57.Revenue of $0.17M beats by $0.03M.The company ended the year with $98.7M in cash and cash equivalents.Press Release For further details see: Lumos Pharma EPS beats by $0.57, beats on revenue

Data published in the Journal of Endocrine Society and accepted for presentation at ENDO 2021 demonstrate distinct mechanism of action and potential efficacy of LUM-201 in subset of pediatric growth hormone deficiency (PGHD) patients Final tranche of $26 million non-dilutive fun...

AUSTIN, Texas, March 04, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that results of peer-reviewed analyses of data from two prior pediatric growth hormone deficiency (PGHD) s...